Trials / Completed
CompletedNCT03359889
PraxbindTM India PMS Program
Post Marketing Surveillance Program of Praxbind Use in India.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PraxbindTM | Drug |
Timeline
- Start date
- 2018-12-26
- Primary completion
- 2020-01-13
- Completion
- 2020-01-13
- First posted
- 2017-12-02
- Last updated
- 2023-08-25
- Results posted
- 2021-02-16
Locations
3 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03359889. Inclusion in this directory is not an endorsement.